Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2025, ...
Amgen (NASDAQ:AMGN) executives highlighted broad-based growth in 2025 and laid out expectations for continued momentum in ...
Amgen delivered a strong fourth quarter of 2025 and looks well-positioned to absorb the LOEs on Prolia, Xgeva, and Ravicti in ...
Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST ...
Investor's Business Daily on MSN
Amgen eyes buy zone after fourth-quarter beat as obesity studies mount
Amgen is running a number of studies of its obesity drug, MariTide.
Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but it has expanded its portfolio to include innovative drugs in therapeutic areas ranging from ...
The California-based biotech company's quarterly revenue rose 9% from a year earlier to $9.9 billion, which beat the average ...
The Manila Times on MSN
Amgen's Q4 results beat expectations, shares rise modestly
AMGEN on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, sending its shares modestly higher as the company continues to express confidence in ...
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight ...
Looking ahead, Amgen issued 2026 guidance with revenue projected between $37.0 billion and $38.4 billion, compared to the consensus estimate of $37.1 billion. The company expects adjusted EPS of ...
Amgen Inc. stock has reached an all-time high, hitting $353.74, marking a significant milestone for the biotechnology company. With a substantial market cap of $190 billion, InvestingPro analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results